| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Haemagglutinin of influenza virus (fowl plague virus). Triperiden targets the haemagglutinin of fowl plague virus (FPV) for antiviral activity and acts by inhibiting the conformational change in the haemagglutinin at acid pH.
|
|---|---|
| ln Vitro |
In vitro, Triperiden inhibits influenza virus multiplication. It targets the haemagglutinin of fowl plague virus (FPV) and inhibits the conformational change in the haemagglutinin at acid pH. This prevents viral entry and fusion with host cells. Triperiden also has anticholinergic activity and is used as an anti-parkinsonism drug.
|
| ln Vivo |
In vivo, Triperiden is an inhibitor of influenza virus multiplication. It has been studied in animal models of influenza infection. The compound also has anticholinergic anti-parkinsonism activity. Further details on in vivo efficacy are available in the primary research literature.
|
| Enzyme Assay |
Non-cell binding assays for Triperiden are performed using purified haemagglutinin protein from fowl plague virus. Binding studies are conducted using surface plasmon resonance (SPR) or ELISA-based assays. Haemagglutinin is immobilized on a sensor chip or plate, and varying concentrations of Triperiden (0.001-100 μM) are flowed over the surface. Binding affinity (KD) is calculated from sensorgrams or binding curves. The inhibition of acid-induced conformational change is assessed by circular dichroism or trypsin sensitivity assays.
|
| Cell Assay |
Cellular antiviral assays are performed using MDCK cells infected with influenza virus. Cells are treated with Triperiden at concentrations ranging from 0.01-100 μM. Viral replication is assessed by plaque reduction assay or by measuring viral titers (TCID₅₀) in culture supernatants. The IC₅₀ for inhibition of viral replication is calculated from dose-response curves. Cytotoxicity is evaluated using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
In vivo animal studies are conducted in mouse models of influenza infection. Triperiden is administered via intraperitoneal or oral routes at doses determined from pharmacokinetic studies. Efficacy endpoints include survival, viral load in lungs (TCID₅₀ or qPCR), and histopathological analysis of lung tissue. The compound's activity against fowl plague virus is evaluated, and protection against lethal challenge is assessed.
|
| ADME/Pharmacokinetics |
Published pharmacokinetic data for Triperiden are limited. The compound has a molecular weight of 347.92 and a molecular formula of C21H30ClNO. It is soluble in DMSO. Triperiden is also an anticholinergic agent with anti-parkinsonism activity. Further studies on oral bioavailability, half-life, and metabolism would be required for therapeutic development.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for Triperiden are limited to research use. As an anticholinergic agent, it may cause dry mouth, blurred vision, constipation, and urinary retention at high doses. No significant organ-specific toxicity has been reported at effective antiviral doses. Standard safety pharmacology studies would be required for therapeutic development. The compound is for research use only.
|
| References | |
| Additional Infomation |
Triperiden is an inhibitor of influenza virus multiplication that targets the haemagglutinin of fowl plague virus and inhibits the conformational change in haemagglutinin at acid pH. It is also an anticholinergic anti-parkinsonism drug. The compound's dual activity makes it a unique research tool for studying both viral entry mechanisms and cholinergic signaling. Triperiden is not approved for clinical use as an antiviral and is available for research purposes only.
|
| Molecular Formula |
C21H30CLNO
|
|---|---|
| Molecular Weight |
347.927
|
| Exact Mass |
347.202
|
| CAS # |
14617-17-5
|
| PubChem CID |
161077
|
| Appearance |
Off-white to light yellow solid powder
|
| Boiling Point |
463ºC at 760mmHg
|
| Flash Point |
228.9ºC
|
| Vapour Pressure |
2.26E-09mmHg at 25°C
|
| LogP |
4.392
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
427
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
HWSIZQMXQQXDNZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H29NO.ClH/c23-21(16-7-3-1-4-8-16,9-12-22-10-5-2-6-11-22)20-15-13-17-18(14-15)19(17)20;/h1,3-4,7-8,15,17-20,23H,2,5-6,9-14H2;1H
|
| Chemical Name |
1-phenyl-3-piperidin-1-yl-1-(3-tricyclo[2.2.1.02,6]heptanyl)propan-1-ol;hydrochloride
|
| Synonyms |
Norakin; Triperiden
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~95.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.19 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.19 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.19 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8741 mL | 14.3707 mL | 28.7414 mL | |
| 5 mM | 0.5748 mL | 2.8741 mL | 5.7483 mL | |
| 10 mM | 0.2874 mL | 1.4371 mL | 2.8741 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
